Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013
Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kobayashi Masanori, Sakabe Tomoyo, Abe Hirofumi, Tanii Mitsugu, Takahashi Hidenori, Chiba Asako, Yanagida Eri, Shibamoto Yuta, Ogasawara Masahiro, Tsujitani Shun-ichi, Koido Shigeo, Nagai Kazuhiro, Shimodaira Shigetaka, Okamoto Masato, Yonemitsu Yoshikazu, Suzuki Noboru, Nagaya Masaki, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
Аннотация
BACKGROUND: The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs).
METHODS: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined.
RESULTS: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023).
CONCLUSIONS: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.
METHODS: Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined.
RESULTS: No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023).
CONCLUSIONS: Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.
Предметные рубрики MeSH
AgedAged, 80 and overBile Duct NeoplasmsBile Ducts, ExtrahepaticBile Ducts, IntrahepaticBiliary Tract NeoplasmsCancer VaccinesCholangiocarcinomaDendritic CellsFemaleGallbladder NeoplasmsHumansImmunotherapy, ActiveMaleMiddle AgedMucin-1Retrospective StudiesSurvival AnalysisTreatment OutcomeWT1 Proteins